Literature DB >> 2531788

Impaired nerve regeneration in streptozotocin-diabetic rats. Effects of treatment with an aldose reductase inhibitor.

A R Ekström1, D R Tomlinson.   

Abstract

Rats with streptozotocin-induced diabetes have a decreased rate of sciatic nerve regeneration. We studied the effects on this defect of treatment with the aldose reductase inhibitor, ponalrestat (25 mg/kg per day via an endogastric tube). The nerves of diabetic rats were crush-injured at 5 weeks of diabetes and regeneration evaluated 7 days later with the pinch-reflex test. Ponalrestat treatment was started at day 3 after streptozotocin injection and was continued for the whole experimental period, i.e. until 6 weeks of diabetes. The treatment prevented effectively the accumulation of sorbitol and fructose in the nerves of diabetic rats, but was without effect on the sciatic nerve regeneration (controls 21.8 +/- 1.2 mm/7 days (mean +/- SEM, n = 6), untreated diabetics 15.8 +/- 1.8 (n = 7), ponalrestat-treated diabetics 16.2 +/- 1.0 (n = 10]. The results indicate that there is no connection between increased sorbitol pathway flux and impaired regeneration in streptozotocin diabetic rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531788     DOI: 10.1016/0022-510x(89)90193-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy.

Authors:  Gigi J Ebenezer; Ryan O'Donnell; Peter Hauer; Nicholas P Cimino; Justin C McArthur; Michael Polydefkis
Journal:  Brain       Date:  2011-06       Impact factor: 13.501

Review 2.  The role of axonal cytoskeleton in diabetic neuropathy.

Authors:  W G McLean
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

3.  Impaired induction of nerve ornithine decarboxylase activity in the streptozotocin-diabetic rat is prevented by the aldose reductase inhibitor ponalrestat.

Authors:  C Pekiner; W G McLean
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

4.  Diabetes mellitus prevents capsaicin from inducing hyperaemia in the rat sciatic nerve.

Authors:  D W Zochodne; L T Ho
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

5.  Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling.

Authors:  Bogdan Beirowski; Jason Gustin; Sean M Armour; Hiroyasu Yamamoto; Andreu Viader; Brian J North; Shaday Michán; Robert H Baloh; Judy P Golden; Robert E Schmidt; David A Sinclair; Johan Auwerx; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

6.  Impaired nerve fiber regeneration in axotomized peripheral nerves in streptozotocin-diabetic rats.

Authors:  Naoki Nishida; Shin-Ichiro Yamagishi; Hiroki Mizukami; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2013-06-28       Impact factor: 4.232

7.  Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes.

Authors:  Masaki Kondo; Hideki Kamiya; Tatsuhito Himeno; Keiko Naruse; Eitaro Nakashima; Atsuko Watarai; Taiga Shibata; Takahiro Tosaki; Jiro Kato; Tetsuji Okawa; Yoji Hamada; Ken-Ichi Isobe; Yutaka Oiso; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2014-09-11       Impact factor: 4.232

8.  Exogenous neuritin treatment improves survivability and functions of Schwann cells with improved outgrowth of neurons in rat diabetic neuropathy.

Authors:  Chunhong Xi; Yingduan Zhang; Mei Yan; Qing Lv; Huan Lu; Jun Zhou; Yucheng Wang; Jianbo Li
Journal:  J Cell Mol Med       Date:  2020-07-15       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.